Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 3
1983 2
1984 4
1985 5
1986 11
1987 13
1988 13
1989 10
1990 12
1991 19
1992 23
1993 14
1994 13
1995 19
1996 27
1997 24
1998 26
1999 14
2000 14
2001 22
2002 18
2003 9
2004 19
2005 21
2006 16
2007 16
2008 18
2009 19
2010 14
2011 16
2012 14
2013 23
2014 26
2015 36
2016 32
2017 31
2018 29
2019 38
2020 39
2021 51
2022 58
2023 49
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

838 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for apob cancer
Search for APOBR cancer instead (2 results)
Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis.
Hendriks D, Brouwers JF, Hamer K, Geurts MH, Luciana L, Massalini S, López-Iglesias C, Peters PJ, Rodríguez-Colman MJ, Chuva de Sousa Lopes S, Artegiani B, Clevers H. Hendriks D, et al. Nat Biotechnol. 2023 Nov;41(11):1567-1581. doi: 10.1038/s41587-023-01680-4. Epub 2023 Feb 23. Nat Biotechnol. 2023. PMID: 36823355 Free PMC article.
Here we use human fetal hepatocyte organoids to model the first stage of NAFLD, steatosis, representing three different triggers: free fatty acid loading, interindividual genetic variability (PNPLA3 I148M) and monogenic lipid disorders (APOB and MTTP mutations). Screening …
Here we use human fetal hepatocyte organoids to model the first stage of NAFLD, steatosis, representing three different triggers: free fatty …
Emerging Evidence of Pathological Roles of Very-Low-Density Lipoprotein (VLDL).
Huang JK, Lee HC. Huang JK, et al. Int J Mol Sci. 2022 Apr 13;23(8):4300. doi: 10.3390/ijms23084300. Int J Mol Sci. 2022. PMID: 35457118 Free PMC article. Review.
Emerging evidence suggests disturbed VLDL metabolism in sleep disorders and in cancer development and progression. In addition to VLDL, the VLDL receptor (VLDLR) may affect both VLDL metabolism and carcinogenesis. ...
Emerging evidence suggests disturbed VLDL metabolism in sleep disorders and in cancer development and progression. In addition to VLD …
Apolipoproteins, lipids and risk of cancer.
Borgquist S, Butt T, Almgren P, Shiffman D, Stocks T, Orho-Melander M, Manjer J, Melander O. Borgquist S, et al. Int J Cancer. 2016 Jun 1;138(11):2648-56. doi: 10.1002/ijc.30013. Epub 2016 Feb 8. Int J Cancer. 2016. PMID: 26804063 Free article.
Among men, ApoB was positively associated with cancer risk (HRadj ApoB = 1.06, 95%CI: 1.01,1.10). Female breast cancer risk was inversely associated with ApoB (HRadj = 0.92, 95%CI: 0.86,0.99). ...
Among men, ApoB was positively associated with cancer risk (HRadj ApoB = 1.06, 95%CI: 1.01,1.10). Female breast canc …
Hypoxia-Responsive lncRNA AC115619 Encodes a Micropeptide That Suppresses m6A Modifications and Hepatocellular Carcinoma Progression.
Zhang Q, Wei T, Yan L, Zhu S, Jin W, Bai Y, Zeng Y, Zhang X, Yin Z, Yang J, Zhang W, Wu M, Zhang Y, Liu L. Zhang Q, et al. Cancer Res. 2023 Aug 1;83(15):2496-2512. doi: 10.1158/0008-5472.CAN-23-0337. Cancer Res. 2023. PMID: 37326474
Long noncoding RNAs (lncRNA) regulate a number of aspects of cancer biology. Recent research has shown that lncRNAs can encode micropeptides that mediate their functions in tumors. ...AC115619 was cotranscribed with the adjacent upstream coding gene APOB, and hypoxi …
Long noncoding RNAs (lncRNA) regulate a number of aspects of cancer biology. Recent research has shown that lncRNAs can encode microp …
Response.
Byers T, Goff D. Byers T, et al. J Natl Cancer Inst. 2015 Sep 12;107(10):djv243. doi: 10.1093/jnci/djv243. Print 2015 Oct. J Natl Cancer Inst. 2015. PMID: 26364305 No abstract available.
APOB Genotypes and CDH13 Haplotypes in the Cholesterol-Related Pathway Genes Predict Non-Small Cell Lung Cancer Survival.
Deng W, Liu H, Luo S, Clarke J, Glass C, Su L, Lin L, Christiani DC, Wei Q. Deng W, et al. Cancer Epidemiol Biomarkers Prev. 2020 Jun;29(6):1204-1213. doi: 10.1158/1055-9965.EPI-19-1262. Epub 2020 Apr 1. Cancer Epidemiol Biomarkers Prev. 2020. PMID: 32238407 Free PMC article.
However, the roles of genetic variants of the cholesterol pathway genes in cancer survival remain unclear. METHODS: We investigated associations between 26,781 common SNPs in 209 genes of the cholesterol pathway and non-small cell lung cancer (NSCLC) survival by uti …
However, the roles of genetic variants of the cholesterol pathway genes in cancer survival remain unclear. METHODS: We investigated a …
Cholesterol and breast cancer risk: a systematic review and meta-analysis of prospective studies.
Touvier M, Fassier P, His M, Norat T, Chan DS, Blacher J, Hercberg S, Galan P, Druesne-Pecollo N, Latino-Martel P. Touvier M, et al. Br J Nutr. 2015 Aug 14;114(3):347-57. doi: 10.1017/S000711451500183X. Epub 2015 Jul 15. Br J Nutr. 2015. PMID: 26173770 Free article. Review.
Overall, the summary HR for the association between TC and breast cancer risk was 0.97 (95% CI 0.94, 1.00; dose-response per 1 mmol/l increment, thirteen studies), and that between HDL-C and breast cancer risk was 0.86 (95% CI 0.69, 1.09; dose-response per 1 mmol/l …
Overall, the summary HR for the association between TC and breast cancer risk was 0.97 (95% CI 0.94, 1.00; dose-response per 1 mmol/l …
Hypobetalipoproteinemia and abetalipoproteinemia.
Welty FK. Welty FK. Curr Opin Lipidol. 2014 Jun;25(3):161-8. doi: 10.1097/MOL.0000000000000072. Curr Opin Lipidol. 2014. PMID: 24751931 Free PMC article. Review.
PURPOSE OF REVIEW: Several mutations in the apoB, proprotein convertase subtilisin/kexin type 9 (PCSK9), and MTP genes result in low or absent levels of apoB and LDL-cholesterol in plasma, which cause familial hypobetalipoproteinemia and abetalipoproteinemia. ...Pha …
PURPOSE OF REVIEW: Several mutations in the apoB, proprotein convertase subtilisin/kexin type 9 (PCSK9), and MTP genes result in low …
Roles of ApoB-100 gene polymorphisms and the risks of gallstones and gallbladder cancer: a meta-analysis.
Gong Y, Zhang L, Bie P, Wang H. Gong Y, et al. PLoS One. 2013 Apr 18;8(4):e61456. doi: 10.1371/journal.pone.0061456. Print 2013. PLoS One. 2013. PMID: 23637837 Free PMC article.
BACKGROUND: Gallstones (GS) is the major manifestation of gallbladder disease, and is the most common risk factor for gallbladder cancer (GBC). Previous studies investigating the association between ApoB-100 gene polymorphisms and the risks of GS and GBC have yielde …
BACKGROUND: Gallstones (GS) is the major manifestation of gallbladder disease, and is the most common risk factor for gallbladder cancer …
838 results